Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Other Non-Current Liabilities (2017 - 2025)

Eton Pharmaceuticals' Other Non-Current Liabilities history spans 2 years, with the latest figure at $5.2 million for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 186.39% to $5.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.2 million, a 186.39% increase, with the full-year FY2025 number at $5.2 million, up 186.39% from a year prior.
  • Other Non-Current Liabilities hit $5.2 million in Q4 2025 for Eton Pharmaceuticals, up from $3.9 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for ETON hit a ceiling of $5.2 million in Q4 2025 and a floor of $1.8 million in Q4 2024.